Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

Thase, Michael E.; Fayyad, Rana; Cheng, Ru-fong J.; Guico-Pabia, Christine J.; Sporn, Jonathan; Boucher, Matthieu; Tourian, Karen A.

doi:10.1185/03007995.2015.1020365

Cited by 9 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a pooled analysis of short-term studies on desvenlafaxine, there were significant increases in supine systolic BP and supine diastolic BP in the pooled desvenlafaxine 50- and 100-mg groups compared with those in the placebo group [ 14 ]. By contrast, long-term safety regarding BP change was documented in a double-blind, placebo-controlled, randomized withdrawal study with 50 mg/d of desvenlafaxine, where there was no significant BP change at the final evaluation when compared to the placebo [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…The side-effect profile of desvenlafaxine was found consistent with that of other SNRIs and the efficacy of desvenlafaxine has been demonstrated through short- and long-term clinical trials, but these included few Asian participants [ 11 - 13 ]. As an SNRI, desvenlafaxine may also result in blood pressure (BP) elevation [ 10 , 14 ]. However, this has not been confirmed in the Asian population, especially over a long-term period.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study

Roh

Lee

Choi

et al. 2022

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective: Although the safety and efficacy of desvenlafaxine have been demonstrated, long-term evidence in Asians is lacking. We examined the safety and effectiveness of desvenlafaxine for up to 6 months in routine clinical practice in Korea. Methods: This multicenter, open-label, prospective observational study was conducted from February 2014 to February 2020 as a postmarketing surveillance study of desvenlafaxine (ClinicalTrials.gov identifier: NCT02548949). Adult patients with major depressive disorder (MDD) were observed from the initiation of treatment for 8 weeks (acute treatment phase) and then up to 6 months (continuation treatment phase) in a subsample. Safety was evaluated by incidence of adverse events (AE) and adverse drug reactions. Treatment response was assessed using the Clinical Global Impression-Improvement (CGI-I) scale. Results: We included 700 and 236 study subjects in the analysis of acute and continuation treatment phase, respectively. In acute treatment phase, AE incidence was 9.86%, with nausea being most common (2.00%). In continuation treatment phase, AE incidence was 2.97%, with tremor occurring most frequently. After acute treatment (n = 464), the treatment response rate according to the CGI-I score at week 8 was 28.9%. In long-term users (n = 213), the response rate at month 6 was 45.5%. During the study period, no clinically relevant changes in BP were found regardless of concomitant use of antihypertensive drugs. Conclusion: This study provides evidence on the safety and effectiveness of desvenlafaxine in adults with MDD, with a low incidence of AE, consistent AE profile with previous studies, and improved response after long-term treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study

Roh

Lee

Choi

et al. 2022

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

show abstract

“…Some studies have shown a small but significant increase in blood pressure. 36,37 However, Speroff et al, 26 did not find a difference in adverse effects with placebo after 52 weeks of treatment.…”

Section: Pharmacological Approachesmentioning

confidence: 94%

Dealing with vasomotor symptoms in patients with breast cancer, what options do we have?

Susana¹

2018

IJFCM

View full text Add to dashboard Cite

show abstract

“…Los efectos secundarios, como náuseas, insomnio y sequedad bucal, fueron observados solamente en la primera semana de tratamiento. Algunos estudios han mostrado un pequeño pero significativo aumento en la presión arterial (26,27) . Sin embargo, Speroff y col (16) no encuentran diferencia con el placebo en los efectos adversos, luego de 52 semanas de tratamiento.…”

Section: Introductionunclassified

Tratamiento de los síntomas vasomotores en pacientes con cáncer de mama. Revisión narrativa

Susana

Marina

Nardo

et al. 2018

Rev peru ginecol obstet.

View full text Add to dashboard Cite

Rev Peru Ginecol Obstet. 2018;64(1) 69 RESUMENLas mujeres con antecedentes de cáncer de mama suelen experimentar síntomas vasomotores más severos y frecuentes que la población general. Numerosos trabajos han demostrado que los síntomas vasomotores (SVM) son los efectos adversos más frecuentes de la terapia adyuvante, y que hasta 20% de las pacientes con cáncer de mama considera discontinuar el tratamiento debido a estos síntomas, a pesar de su beneficio en la reducción de la recurrencia. Mientras que la terapia sustitutiva hormonal (THM) es usada regularmente en mujeres sanas para tratamiento de los SVM, está contraindicada en pacientes con antecedente de cáncer de mama. Existen muy pocos datos clínicos sobre las intervenciones no farmacológicas, y el papel de las terapias alternativas y complementarias sigue siendo controvertido. La revisión de la literatura da cuenta de que estos agentes farmacológicos, los inhibidores de la recaptación de serotonina-norepinefrina (IRNSs), los inhibidores selectivos de la recaptación de serotonina (IRSs), los antihipertensivos y los anticonvulsivos, disminuyen la intensidad y frecuencia de los SVM, demostrando una mejoría clínicamente significativa. Sin embargo, algunos IRSSs e IRSNs son potentes inhibidores del citocromo P450 2D6 (CYP 2D6), lo que impacta en la concentración de endoxifeno, debiendo ser evitados en pacientes tratadas con tamoxifeno. Son una opción el citalopram y la venlafaxina, si bien su consecuencia sobre la recurrencia y supervivencia del cáncer de mama es controvertida. La eficacia en el tratamiento de los SVM con antidepresivos es menor que con estrógenos y hay pocas publicaciones comparando ambos tratamientos. Faltan datos sobre el lapso de la indicación. Dos fármacos antiepilépticos también han demostrado efectividad, la gabapentina y la pregabalina. Algunas investigaciones comparativas están en curso, y habrá que esperar sus resultados para individualizar cuál es el óptimo en el manejo de los síntomas menopáusicos en mujeres que han padecido cáncer de mama. Palabras clave. Cáncer de mama, Síntomas vasomotores, Antihipertensivos, Antidepresivos, Antiepilépticos. ABSTRACTWomen with a history of breast cancer tend to have more severe and frequent vasomotor symptoms than the general population. Numerous studies have shown that vasomotor symptoms (VMS) are the most frequent adverse event of adjuvant therapy, and that up to 20% of breast cancer patients consider discontinuing treatment because of these symptoms, despite their benefit in the reduction of recurrence. While hormone replacement therapy (HRT) is regularly used in healthy women to treat VMS, it is contraindicated in patients with history of breast cancer. There are few clinical data on non-pharmacological interventions, and the role of alternative and complementary therapies remains controversial. The review of the literature reveals that these pharmacological agents, serotonin-norepinephrine reuptake inhibitors (SSRIs), selective serotonin reuptake inhibitors (IRSs), antihypertensives and antic...

show abstract

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

Abstract: Short-term desvenlafaxine treatment was associated with small but statistically significant increases in SSBP and SDBP.

Cited by 9 publications

References 37 publications

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study

Dealing with vasomotor symptoms in patients with breast cancer, what options do we have?

Tratamiento de los síntomas vasomotores en pacientes con cáncer de mama. Revisión narrativa

Contact Info

Product

Resources

About